Teleflex Incorporated TFX

Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.

Con 8 acciones de TFX (USD 1.002,16) habrías recibido USD 10,88 en dividendos en los últimos 12 meses.

• Zacks Investment Research 30 sept

  Boston Scientific's MedSurg Diversification Bolsters Growth Prospects

  Boston Scientific's MedSurg segment showed mixed Q2 2026 results with Endoscopy growing 7% and Neuromodulation up 12%, but Urology disappointed with only 1% growth due to sacral neuromodulation recovery delays and stone management portfolio gaps. The company expects flat to low-single digit Urology growth for full-year 2026 but remains confident in 2027 improvement with planned product launches. BSX stock has underperformed the industry and carries a Zacks Rank #4 (Sell) rating.

  

• Zacks Investment Research 23 sept

  Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now

  Bio-Rad Laboratories (BIO) shows modest growth in Clinical Diagnostics with quality controls and blood typing leading, supported by strong international presence. However, China weakness, geopolitical volatility, and foreign exchange headwinds constrain full-year outlook. The company maintains a Hold rating with reaffirmed guidance of 3% decline to 0.5% growth for 2026.

  

• Zacks Investment Research 22 sept

  Is This the Right Time to Add DGX Stock to Your Portfolio?

  Quest Diagnostics (DGX) is experiencing growth across physician, hospital, and consumer channels, driven by customer wins and an expanding advanced diagnostics portfolio delivering double-digit growth. The company targets 3% annual cost savings through AI and automation initiatives. However, reimbursement uncertainty, cost pressures, and elevated debt of $5.63 billion remain concerns that could impact margins and financial flexibility.

  

• Zacks Investment Research 16 sept

  Reasons to Retain Penumbra Stock in Your Portfolio for Now

  Penumbra (PEN) reported Q2 2026 revenues up 14.9% driven by thrombectomy and embolization products, with international sales growing 7.6% across 100+ countries. However, SG&A expenses grew faster than revenues at 24.1%, causing operating margins to compress. Foreign exchange exposure and macroeconomic sensitivity pose risks, though the company maintains a Zacks Rank #3 (Buy) rating with shares up 21.1% over the past year.

  

• Zacks Investment Research 15 sept

  Is This the Right Time to Retain Resmed Stock in Your Portfolio?

  Resmed is divesting its MatrixCare business for $490 million to streamline its Residential Care Software segment and focus on higher-growth platforms. The company's Masks segment showed strong 13% revenue growth in fiscal 2026, driven by product innovation and improved compliance rates. However, macroeconomic pressures and intense competition pose operational risks.